Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.
Sai K, Saito Y, Maekawa K, Kim SR, Kaniwa N, Nishimaki-Mogami T, Sawada J, Shirao K, Hamaguchi T, Yamamoto N, Kunitoh H, Ohe Y, Yamada Y, Tamura T, Yoshida T, Matsumura Y, Ohtsu A, Saijo N, Minami H.
Sai K, et al. Among authors: ohe y.
Cancer Chemother Pharmacol. 2010 May;66(1):95-105. doi: 10.1007/s00280-009-1138-y. Epub 2009 Sep 22.
Cancer Chemother Pharmacol. 2010.
PMID: 19771428
Clinical Trial.